medicine-news-1/bishops-to-house-3a-keep-abortion-funding-out-of-health-care-reform--make-health-care-available-to-vulnerable-60878-4/;menu1239.additem(

Breaking Biology Technology:Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 2 Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 3 New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2 New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3 Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2 MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2 MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3 MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4

[0] Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors [0] New silicon-germanium nanowires could lead to smaller, more powerful electronic devices [0] Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease [0] MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products

Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2 ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3 ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6 Lack of happiness hormone serotonin in the brain causes impaired maternal behavior in mice 8972 1 Energy saving method checks refrigerant level in air conditioners 8970 1 Energy saving method checks refrigerant level in air conditioners 8970 2 How to text message and avoid pain 8968 1 How to text message and avoid pain 8968 2

[0] Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg [0] ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)[0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer